GDPD3 Deficiency Alleviates Neuropathic Pain and Reprograms Macrophagic Polarization Through PGE2 and PPARγ Pathway

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Neuropathic pain involves complex central and peripheral pathways, making effective cures elusive.
• Inflammation in dorsal root ganglia (DRG) contributes significantly to neuropathic pain.
• Current treatments, like nonsteroidal anti-inflammatory drugs, offer limited efficacy.

Purpose of the Study:

• To investigate the role of the Gdpd3 gene in neuropathic pain.
• To explore the mechanism by which Gdpd3 deficiency impacts pain and neuroinflammation.
• To identify potential therapeutic targets for neuropathic pain management.

Main Methods:

• Investigated Gdpd3 gene deficiency in a mouse model of neuropathic pain.
• Analyzed inflammatory responses, including prostaglandin E2 (PGE2) and phosphatidylethanolamine (PE) levels in DRG.
• Utilized RNA sequencing to identify related pathways in Gdpd3-deficient bone marrow-derived macrophages (BMDMs).
• Examined macrophage polarization (M1 vs. M2 phenotype) and the involvement of the PPARγ/FABP4 pathway.

Main Results:

• Gdpd3 deficiency significantly alleviated neuropathic pain, outperforming Celecoxib.
• Reduced levels of inflammatory mediators PE (20:4) and PGE2 were observed in the DRG of Gdpd3-deficient mice.
• Gdpd3 deficiency promoted a shift in macrophage polarization from M1 to M2 phenotype.
• The PPARγ/FABP4 pathway was identified as crucial, with Gdpd3 deficiency upregulating PPARγ, and its inhibition reversing macrophage reprogramming.

Conclusions:

• Gdpd3 deficiency exerts a potent analgesic effect on neuropathic pain.
• The mechanism involves alleviating neuroinflammation in DRG by modulating macrophage polarization.
• This modulation is mediated through the PGE2 and PPARγ/FABP4 signaling pathway, highlighting Gdpd3 as a potential therapeutic target.